CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity - PubMed (original) (raw)
Review
CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity
A W Tong et al. Leuk Lymphoma. 1996 Mar.
Abstract
CD40 is a 48 kDa glycosylated phospoprotein that is a member of the tumor necrosis factor receptor (TNF-R) superfamily. CD40 was originally identified in B lymphocytes, and is found on monocytes, dendritic cells, some carcinoma cell lines, and the thymic epithelium. CD40 is expressed on normal pre-B through mature B stages of differentiation. For normal B cells, the cross-linking of CD40 induces cell cycle progression, long-term proliferation in vitro, IgE secretion, increased adhesion molecule (LFA-1) expression, and low level IL-6 secretion. The natural ligand of CD40 (CD40L, gp39, or T-BAM, for T-B cell activating molecule) was recently identified as an inducible molecule expressed transitionally on activated T cells. Although originally believed to be absent in normal and malignant plasma cells, CD40 has been demonstrated on the majority of myeloma cell lines and myeloma cells from plasma cell dyscrasia (PCD) patient specimens tested. CD40 activation modulated myeloma cell proliferation and clonogenicity in vitro, suggesting that the CD40 pathway is active in myeloma cell growth. For the IL-6 dependent cell line ANBL-6, CD40 activation was associated with autocrine IL-6 production. However, the IL-6 pathway does not appear to play a predominant role in CD40 activation of non-IL-6-dependent MM cell lines and patient primary bone marrow cultures. The possible pathophysiologic role of the CD40 receptor in human multiple myeloma is discussed.
Similar articles
- Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro.
Tong AW, Zhang BQ, Mues G, Solano M, Hanson T, Stone MJ. Tong AW, et al. Blood. 1994 Nov 1;84(9):3026-33. Blood. 1994. PMID: 7524765 - CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line.
Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF. Westendorf JJ, et al. J Immunol. 1994 Jan 1;152(1):117-28. J Immunol. 1994. PMID: 7504707 - CD40 ligand triggered interleukin-6 secretion in multiple myeloma.
Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. Urashima M, et al. Blood. 1995 Apr 1;85(7):1903-12. Blood. 1995. PMID: 7535594 - The CD40 antigen and its ligand.
Banchereau J, Bazan F, Blanchard D, Brière F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S. Banchereau J, et al. Annu Rev Immunol. 1994;12:881-922. doi: 10.1146/annurev.iy.12.040194.004313. Annu Rev Immunol. 1994. PMID: 7516669 Review. - The role of the CD40 antigen on malignant B cells.
Planken EV, Willemze R, Kluin-Nelemans JC. Planken EV, et al. Leuk Lymphoma. 1996 Jul;22(3-4):229-35. doi: 10.3109/10428199609051753. Leuk Lymphoma. 1996. PMID: 8819071 Review.
Cited by
- ZG16 enhances the maturation of dendritic cells via induction of CD40 and contributes to the antitumor immunity in pancreatic cancer.
Meng H, Li L, Nan M, Ding Y, Li Y, Zhang M. Meng H, et al. Oncogene. 2024 Oct;43(43):3184-3196. doi: 10.1038/s41388-024-03154-6. Epub 2024 Sep 11. Oncogene. 2024. PMID: 39261658 - Multiple myeloma: increasing evidence for a multistep transformation process.
Hallek M, Bergsagel PL, Anderson KC. Hallek M, et al. Blood. 1998 Jan 1;91(1):3-21. Blood. 1998. PMID: 9414264 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous